Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 9 Results

Title
Intervention Indication Therapeutic Area Year Actions
Abatacept with a calcineurin inhibitor and methotrexate for prophylaxis of acute graft versus host disease Abatacept (Orencia) Graft versus host disease (GvHD) Immunology 2022 View  |  Download
Belumosudil for graft versus host disease Belumosudil (SLx-2119; KD025; KD-025) Graft versus host disease (GvHD) Immunology 2021 View  |  Download
BPX‐501 to improve Immune Recovery and Graft versus Host Disease (GvHD) after Haploidentical Stem Cell Transplant Rivogenlecleucel (BPX-501) Graft versus host disease (GvHD) , Immunodeficiency Immunology 2018 View  |  Download
Ibrutinib for chronic Graft versus Host Disease Ibrutinib (Imbruvica) Graft versus host disease (GvHD) Immunology 2020 View  |  Download
Inolimomab for acute Graft versus Host Disease Inolimomab (Leukotac; B-B10; BT563) Graft versus host disease (GvHD) Immunology 2021 View  |  Download
Ruxolitinib for acute graft versus host disease (aGvHD) Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2019 View  |  Download
Ruxolitinib for chronic graft versus host disease (cGvHD) Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2019 View  |  Download
Ruxolitinib for grades II-IV treatment-naïve or steroid-refractory acute graft versus host disease Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2023 View  |  Download
Ruxolitinib for treating chronic graft versus host disease after allogeneic stem cell transplant in paediatric patients Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications